Last reviewed 2026-05-24 · How we verify

Cenergermin

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Phase 1 active Small molecule ✓ Verified May 2026

Cenergermin is a Small molecule drug developed by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. It is currently in Phase 1 development. Also known as: Oxervate.

Cenergermin is a medication used to treat Neurotrophic Keratitis, Neurotrophic Keratopathy, and Corneal Ulcer, as indicated by ClinicalTrials.gov. It is administered as a 0.002% solution, as shown in ClinicalTrials.gov and also referred to as Cenegermin-bkbj 20 mcg/mL.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Cenergermin
Also known as	Oxervate
Sponsor	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Cenergermin CI brief — competitive landscape report
Cenergermin updates RSS · CI watch RSS
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's portfolio CI

Frequently asked questions about Cenergermin

What is Cenergermin?

Cenergermin is a Small molecule drug developed by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's.

Who makes Cenergermin?

Cenergermin is developed by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (see full London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's pipeline at /company/london-health-sciences-centre-research-institute-or-lawson-research-institute-of).

Is Cenergermin also known as anything else?

Cenergermin is also known as Oxervate.

What development phase is Cenergermin in?

Cenergermin is in Phase 1.

Manufacturer: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's — full pipeline
Therapeutic area: All drugs in Other
Also known as: Oxervate

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing